Cytokines in human melanoma cells: Synthesis, autocrine stimulation and regulatory functions-an overview

Melanoma Research

Volumn 3, Issue 6, 1993, Pages 425-434

  Krasagakis, K ^a   Garbe, C ^a   Orfanos, C E ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Cytokines; Growth factors; Lymphokines; Melanoma cells

Indexed keywords

ALPHA INTERFERON; BASIC FIBROBLAST GROWTH FACTOR; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; LYMPHOKINE; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR NECROSIS FACTOR;

ARTICLE; AUTOCRINE EFFECT; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MELANOMA CELL; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; CELL DIVISION; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH SUBSTANCES; HUMAN; MELANOMA; NEOPLASM PROTEINS; PHENOTYPE; RECEPTORS, CYTOKINE; RECEPTORS, GROWTH FACTOR;

EID: 0027731486     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/00008390-199311000-00005     Document Type: Article

References (107)

1. Sporn MB, Roberts AB. Peptide growth factors are multifunctional. Nature 1988; 332: 217-219.
2. Balkwill FR, Burke F. The cytokine network. Immunol Today 1989; 10: 299-305.
3. Rothe M, Falanga V. Growth factors. Their biology and promise in dermatologic diseases and tissue repair. Arch Dermatol 1989; 125: 1390-1398.
4. Ibelgaufts H. Lexikon Zytokine. Munich: Medikon Verlae, 1992: 244.
5. Goustin AS, Leof EB, Shipley GD, et al. Growth factors and cancer. Cancer Res 1986; 46; 1015-1029.
6. Todaro GJ, Delarco JE. Growth factors produced by sarcoma virus-transformed cells. Cancer Res 1978; 38:4147-4154.
7. Sporn MB, Roberts AB. Autocrine growth factors and cancer. Nature 1985; 313: 745-747.
8. Eisinger M, Marco O. Selective proliferation of normal human melanocytes in vitro in the presence of phorbol ester and cholera toxin. Proc Natl Acad Sci, USA 1982; 79: 2018-2022.
9. Gilchrest BA, Vrabel MA, Flynn E, et al. Selective cultivation of human melanocytes from newborn and adult epidermis. J Invest Dermatol 1984; 83: 370-376.
10. Halaban R, Ghosh S, Baird A. bFGF is the putative natural growth factor for human melanocytes. In Vitro 1987; 23: 47-52.
11. Herlyn M, Kath R, Williams N, et al. Growth-regulatory factors for normal, premalignant and malignant human cells in vitro. Adv Cancer Res 1990; 54: 213-234.
12. Sauvaigo S, Fretts RE, Riopelie RJ, et at. Autonomous proliferation of MeWo human melanoma cell lines in serum-free medium: Secretion of growth-stimulating activities. Int J Cancer 1986; 37: 123-132.
13. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligonucleotides targeted against basic fibroblast growth factor. Embo J 1989; 8: 3685-3691.
14. Pichon F, Lagarde AE. Autoregulation of MeWo metastatic melanoma cell growth: characterization of intracellular (FGF, MGSA) and secreted (PDGF) growth factors. J Celt Physiol 1990; 140: 344-358.
15. Albino P, Davis BM, Nanus DM. Induction of growth factor RNA expression in human malignant melanoma: Markers of transformation. Cancer Res 1991; 51: 4815-4820.
16. Rodeck U, Melber K, Kath R, et al. Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes. J Invest Dermatol 1991; 97: 20-26.
17. Chenevix-Trench G, Martin NG, Ellem KAO. Gene expression in melanoma cell lines and cultured melanocytes: correlation between levels of c-jw-1, c-myc and p53. Oncogene 1990; 5: 1187-1193.
18. Herlyn M, Thurin J, Balaban G, et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 1985; 45: 5670-5676.
19. Ross AH, Herlyn M, Maul GG, et al. The nerve growth factor receptor in normal and transformed neural crest cells. Ann NY Acad Sci 1986; 486: 115-123.
20. Singletary SE, Baker LF, Spitzer G, et al. Biological effect of epidermal growth factor on the in vitro growth of human tumors. Cancer Res 1987; 47: 403-406.
21. Krasagakis K, Garbe C, Zouboulis ChC, et al. Growth response of human melanoma cell lines to EGF, bFGF, TGF-/J and melanoma cell conditioned medium (CM) in vitro. Arch Dermatol Res 1990; 281: 576.
22. Barnes D, Sato G. Serum-free cell culture: a unifying approach. Cell 1980; 22: 649-655.
23. Krasagakis K. Etablierung serumfreier Kulturen maligner Melanomzellen and der Einfluss von Wachstumsfaktoren auf Wachstum, Differeqjerung und Immunophdnotyp. Thesis. Berlin: Freie Universitat Berlin, 1991: 88.
24. Krasagakis K, Garbe C, Schrier PI, et al. Gene expression and growth modulatory properties of transforming growth factor/?1 (TGF-/?1) in normal and malignant melanocytes in vitro. J Invest Dermatol 1992; 98: 508.
25. Carpenter G, Cohen S. Epidermal growth factor. Annu Rev Biochem 1979; 48: 193-216.
26. Rodeck U, Herlyn M, Menssen HD, et at. Metastatic but not primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int J Cancer 1987; 40: 687-690.
27. Kudlow JE, Khosravi MJ, Kobrin MS, et al. Inabilty of anti-epidermal growth factor receptor monoclonal antibody to block ‘autocrine’ growth stimulation in transforming growth factor-secreting melanoma cells. J Biol Chem 1984; 259: 11895-11900.
28. Roberts AB, Anzano MA, Wakefield LM, et al. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci, USA 1985; 82: 119-123.
29. Cheifetz S, Weatherbee JA, Tsang ML, et al. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 1987; 48: 409-415.
30. Derynck R, Jarrett JA, Chen EY, et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985; 316: 701-705.
31. Mooradian DL, Purchio AF, Furcht LT. Differential effects of transforming growth factor Bl on the growth of poorly and highly metastatic murine melanoma cells. Cancer Res 1990; 50: 273-277.
32. Halaban R, Kwon BS, GhosTi S, et al. bFGF as an autocrine growth factor for human melanomas. Oncogene Res 1988; 3: 177-186.
33. Halaban R, Langdon R, Birchall N, et al. Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes. J Cell Biol 1988; 107: 1611-1619.
34. Richmond A, Lawson DH, Nixon DW, et al. In vitro growth promotion in human malignant melanoma cells by fibroblast growth factor. Cancer Res 1982; 42: 3175-3180.
35. Gordon PR, Treloar VD, Vrabel MA, et al. Relative responsiveness of cultured human epidermal melanocytes and melanoma cells to selected mitogens. J Invest Dermatol 1986; 87: 723-727.
36. Becker D, Lee PL, Rodeck U, et al. Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene 1992; 7: 2303-2313.
37. Dotto GP, Moelmann G, Ghosh S, et al. Transformation of murine melanocytes by basic fibroblast growth factor cDNA and oncogenes and selective suppression of the transformed phenotype in a reconstituted cutaneous environment. J Celt Biol 1989; 109: 3115-3128.
38. Richmond A, Lawson DH, Nixon DW, et al. Extraction of a melanoma growth-stimulatory activity from culture medium conditioned by the Hs094 human melanoma cell line. Cancer Res 1983; 43: 2106-2112.
39. Richmond A, Balentien E, Thomas HG, et al. Molecular characterisation and chromosomal mapping of melanoma growth stimulatory activity, a growth factor structurally related to/J-thromboglobulin. Embo J 1988; 7: 2025-2033.
40. Schroder JM, Christophers E. Human melanoma growth stimulatory activity (MGSA/GRO) is a neutrophil activator. Cytokine 1989; 1: 152-156.
41. Richmond A, Thomas HG. Melanoma growth stimulatory activity: Isolation from human melanoma tumors and characterization of tissue distribution. J Cell Biochem 1988; 36: 185-198.
42. Bordoni R, Fine R, Murray D, et al. Characterization of the role of melanoma growth stimulatory activity (MGSA) in the growth of normal melanocytes, nevocytes, and malignant melanocytes. J Cell Biochem 44: 207-219.
43. Lawson DH, Thomas HG, Roy RGB, el al. Preparation of a monoclonal antibody to melanoma growth stimulatory activity released into serum-free culture medium by Hs0294 malignant melanoma cells. J Cell Biochem 1987; 34: 169-185.
44. Richmond A. The pathogenic role of growth factors in melanoma. Semin Dermatol 1991; 10: 246-255.
45. Ross R. Platelet-derived growth factor. Lancet 1989; 2: 1179-1182.
46. Doolittle RF, Hunkapiller MW, Hood LE, et al. Simian sarcoma virus one gene, v-sis, is derived from the gene (or genes) encoding a platelet-derived growth factor. Science 1983; 221: 275-277.
47. Robbins KC, Antoniades HN, Devare SG, et al. Structural and immunological similarities between simian sarcoma virus gene product(s) and human platelet-derived growth factor. Nature 1983; 305: 605-608.
48. Johnsson A, Betsholz C, Heldin CH, el al. Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus. Nature 1985; 317: 438-441.
49. Westermark B, Jonsson A, Paulson Y, et al. Human melanoma cell lines of primary and metastatic origin express the genes encoding the chains of platelet-derived growth factor (PDGF) and produce a PDGF-like growth factor. Proc Natl Acad Sci, USA 1986; 83: 7197-7200.
50. Armstrong CA, Tara DC, Hart CE, et al. Heterogeneity of cytokine production by human malignant melanoma cells. Exp Dermatol 1992; 1: 37-45.
51. Fabricant RN, deLarco JE, Todaro GJ. Nerve growth factor receptors on human melanoma cells in culture. Proc Natl Acad Sci, USA 1977; 74: 565-569.
52. Peacocke M, Yaar M, Mansur CP, et al. Induction of nerve growth factor receptors on cultured human melanocytes. Proc Natl Acad Sci, USA 1988; 85: 5282-5286.
53. Krasagakis K, Garbe C, Kriiger-Krasagakes S, et al. 12-O-Tetradecanoylphorbol-13-acetate not only modulates proliferation rates but also alters antigen expression and LAK-cell susceptibility of normal human melanocytes in vitro. J Invest Dermatol 1993; 100: 653-659.
54. Mather JP, Sato GH. The growth of mouse melanoma cells in hormone-supplemented, serum-free medium. Exp Cell Res 1979; 120: 191-200.
55. Turner AM, Zsebo KM, Martin F, et at. Nonhematopoie-tic tumor cells express stem cell factor and display c-kit receptors. Blood 1992; 80: 374-381.
56. Funasaka Y, Boulton T, Cobb M, et al. c-Kit-kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol Cell 1992; 3: 197-209.
57. Halaban R, Rubin JS, Funasaka Y, et al. Met and hepato-cyte growth factor/scatter factor signal transduction in normal melanocytes and melanoma cells. Oncogene 1992; 7: 2195-2206.
58. Halaban R, Fan B, Ahn J, et al. Growth factors, receptor kinases, and protein tyrosine phosphatases in normal and malignant melanocytes. J Immunother 1992; 12: 154-161.
59. Samid D, Chang EH, Friedman RE. Biochemical correlates of phenotypic reversion in interferon-treated mouse cells transformed by a human oncogene. Biochem Biophys Res Commun 1984; 119: 21-28.
60. Dani C, Mechti N, Piechaczyk M, et al. Increased rate of degradation of c-myc in RNA of interferon-treated Daudi cells. Proc Natl Acad Sci, USA 1985; 82: 4896-4899.
61. Inglot AD, Pajtasz E. Measurement of antagonistic effects of growth factors and interferons. Methods Ensjmol 1986; 119: 657-667.
62. Creasy AA, Bartholomew JC, Merigan TC. Role of G0-G, arrest in the inhibition of tumor cell growth by interferons. Proc Natl Acad Sci, USA 1980; 77: 1471-1475.
63. Mortarini R, Anichini A, Parmiani G. Heterogeneity for integrin expression and cytokine-mediated VLA modulation can influence the adhesion of human melanoma cells to extracellular matrix proteins. Int J Cancer 1991; 47: 551-559.
64. Lee KH, Lawley TJ, Xu YL, et al. VCAM-1-, ELAM-1-, and ICAM-1-independent adhesion of melanoma cells to cultured human dermal microvascular endothelial cells. J Invest Dermatol 1992; 98: 79-85.
65. Sun WH, Kreisle RA, Phillips AW, et al. In vivo and in vitro characteristics of interleukin 6-transfected B16 melanoma cells. Cancer Res 1992; 52: 5412-5415.
66. Garbe C, Krasagakis K, Zouboulis CC, et al. Antitumor activities of interferon alpha, beta and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis and immunopheno-type. J Invest Dermatol 1990; 95: 231-237.
67. Mortarini R, Belli F, Parmiani G, et al. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rILl-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations. Int J Cancer 1990; 45: 334-341.
68. Hock H, Dorsch M, Kunzendorf U, et al. Mechanisms of rejection induced by tumor cell-targeted gene transfer of interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or interferon gamma. Proc Natl Acad Sci, USA 1993; 90: 2774-2778.
69. Rosenberg SA, Lotze MT, Yang JC, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474-484.
70. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 1990; 50: 3473-3486.
71. Garbe C, Kreuser ED, Zouboulis CC, et al. Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Semin Oncol 1992; 19 (Suppl 4): 63-69.
72. Tyring SK, Klimpel G, Brysk M. Eradication of cultured human melanoma cells by immune interferon and leukocytes. JNCI 1984; 73: 1067-1073.
73. Fisher PB, Miranda AF, Babiss LE. Measurement of the effect of interferons on cellular differentiation in murine and human melanoma cells. Methods Enzymol 1986; 119: 611-618.
74. Zouboulis CC, Garbe C, Kriiger S, et al. Interferons and melanoma: Comparison of the cytostatic and cytotoxic effects of natural and recombinant interferons, tumor necrosis factor-alpha and their combinations on human melanoma cells in vitro. Skin Cancer 1990; 5: 137-145.
75. Krasagakis K, Garbe C, Kriiger S, et al. Effects of interferons on cultured human melanocytes in vitro: Interferon-beta but not -alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol 1991; 97: 364-372.
76. Czarniecki CW, Fennie CW, Powers DB, et al. Synergistic antiviral and antiproliferative activities of Escherichia coli-derived human alpha, beta, and gamma interferons. J Virol 1983; 49: 490-496.
77. Giacomini P, Aguzzi A, Pestka S, et al. Modulation by recombinant DNA leukocyte (alpha) and fibroblast (beta) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells. J Immunol 1984; 133: 1649-1655.
78. Houghton AN, Thomson TM, Gross D, et al. Surface antigens of melanoma and melanocytes. Specificity of induction of la antigens by human gamma-interferon. J Exp Med 1984; 160: 255-269.
79. Maio M, Gulwani B, Langer JA, et al. Modulation by interferons of HLA antigen, high-molecular-weight melanoma associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. Cancer Res 1989; 49: 2980-2987.
80. Ziai MR, Imberti L, Tongson A, et al. Differential modulation by recombinant immune interferon of the expression and shedding of HLA antigens and melanoma associated antigens by a melanoma cell line resistant to the antiproliferative activity of immune interferon. Cancer Res 1985; 45: 5877-5882.
81. Matsui M, Temponi M, Ferrone S. Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. J Immunol 1987; 139: 2088-2095.
82. Becker JC, Dummer R, Hartmann AA, et al. Shedding of ICAM-1 from human melanoma cell lines induced by IFN-y and tumor necrosis factor-alpha. Functional consequences on cell-mediated cytotoxicity. J Immunol 1991; 147: 4398-4401.
83. Klein CE, Steinmayer T, Kaufman D, et al. Identification of a melanoma progression antigen as integrin VLA-2. J Invest Dermatol 1991; 96: 281-284.
84. Kruger-Krasagakes S, Krasagakis K, Garbe C, et al. Loss of cytokine gene expression in human melanoma cells in comparison to normal melanocytes in vitro. J Invest Dermatol 1993; 100: 465.
85. Benicelli JL, Elias J, Kern J, et al. Production of inter-leukin 1 activity by cultured human melanoma cells. Cancer Res 1989; 49: 930-935.
86. Kock A, Schwarz T, Micksche M, et al. Cytokines and human malignant melanoma. Immuno- and growth-regulatory peptides in melanoma biology. Cancer Treat Rev 1991; 54: 41-66.
87. Burrows FJ, Haskard DO, Bart IR, et al. Influence of tumor-derived interleukin 1 on melanoma-endothelial cell interactions in vitro. Cancer Res 1991; 51: 4768-4775.
88. Nakai S, Mizuno K, Kaneta M, et al. A simple, sensitive bioassay for the detection of interleukin-1 using human melanoma A375 cell line. Biochem Biophys Res Commun 1988; 154: 1189-1196.
89. Morinaga Y, Suzuki H, Takatsuki F, et al. Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines. J Immunol 1989; 143: 3538-3542.
90. te Velde AA, vd Wiel Kemenade E, Figdor CG. Differential cytostatic activity of monocytes-derived cytokines against human melanoma cells. Int J Cancer 1992; 50: 746-751.
91. Swope VB, Abdel-Malek ZA, Sauder DN, et al. A new role for epidermal cell-derived thymocyte activating fac-tor/IL-1 as an antagonist for distinct epidermal cell function. J Immunol 1989; 142: 1943-1949.
92. Hoon DS, Banez M, Okun E, et al. Modulation of human melanoma cells by interleukin-4 and in combination with gamma-interferon or alpha-tumor necrosis factor. Cancer Res 1991; 51: 2002-2008.
93. Krasagakis K, Kruger-Krasagakes S, Garbe C, et al. rlL-la, ilLAB, rIL-6, rIFN-y, rTNF-a and rTNF-b inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro. J Invest Dermatol 1993; 100: 453.
94. Swope VB, Abdel-Malek Z, Kassem LM, et al. Interleukins 1 alpha and 6 and tumor necrosis factor-alpha are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991; 96: 180-185.
95. Kirnbauer R, Chavrat B, Schauer E, et al. Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: Evidence for a regulatory role of IL-6, IL-7, TNF-b, and UVB light. J Invest Dermatol 1991; 98: 320-326.
96. Aggavral BB. Tumor necrosis factors TNF-a and TNF-p: Their structure and pleiotropic biological effects. Drugs of the Future 1987; 12: 891-898.
97. Colombo MP, Maccalli C, Mattei C, et al. Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. Melanoma Res 1992; 2: 181-189.
98. Zouboulis CC, Schroder K, Garbe C, et al. Cytostatic and cytotoxic effects of recombinant tumor necrosis factor-alpha on sensitive human melanoma cells in vitro may result in selection of cells with enhanced markers of malignancy. J Invest Dermatol 1990; 95: 223-230.
99. Ruggiero V, Tavernier J, Fiers W, et al. Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. J Immunol 1986; 136: 2445-2450.
100. Maio M, Gulwani B, Morgano A, et al. Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. Int J Cancer 1989; 44: 554-559.
101. Schreiber AB, Winkler M, Derynck R. Transforming growth factor-a: a more potent angiogenic mediator than epidermal growth factor. Science 1986; 232: 1250-1253.
102. Roberts AB, Sporn MB, Assoian RK, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci, USA 1986; 83: 4167-4171.
103. Gospodarowicz D, Bialecki H, Thakral TK. The angiogenic activity of the fibroblast and epidermal growth factor. Exp Eye Res 1979; 28: 501-514.
104. Presta M, Maier JAM, Ragnotti G. The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells. J Cell Biol 1989; 109: 1877-1884.
105. Kasid A, Morecki S, Aebersold P, et al. Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci, USA 1990; 87: 473-477.
106. Barth RJ Jr, Mule JJ, Spiess PJ, et al. Interferon gamma and tumor necrosis factor have a role in tumor regression mediated by murine CD8 + tumor infiltrating lymphocytes. J Exp Med 1991; 173: 647-658.
107. Palmieri G, Morrone S, Lollini PL, et al. TNF impairs in vivo and in vitro natural killer (NK) susceptibility of 16 melanoma cells. Scand J Immunol 1992; 35: 279-287.